[
  {
    "ts": null,
    "headline": "Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025",
    "summary": "Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States TOKYO and CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tok",
    "url": "https://finnhub.io/api/news?id=67fce9433f54c02db77f030995ce25d438b9ac641e15209fd68e3267e3e0be53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764803400,
      "headline": "Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025",
      "id": 137678302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States TOKYO and CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tok",
      "url": "https://finnhub.io/api/news?id=67fce9433f54c02db77f030995ce25d438b9ac641e15209fd68e3267e3e0be53"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?",
    "summary": "Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=b2c6e9bbdc03e79f666abe8a7ddd701132097f4a9832ea75ed5f6a04dddda5f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764779411,
      "headline": "Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?",
      "id": 137678303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=b2c6e9bbdc03e79f666abe8a7ddd701132097f4a9832ea75ed5f6a04dddda5f9"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript",
    "summary": "Biogen Inc. (BIIB) Piper Sandler 37th Annual Healthcare Conference December 3, 2025 11:30 AM ESTCompany ParticipantsUptal Patel - Chief Medical...",
    "url": "https://finnhub.io/api/news?id=e69020844686310ebfe1cda1056e6c51c2fdd4d024d5e63093673007663df2fb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764770605,
      "headline": "Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript",
      "id": 137673840,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (BIIB) Piper Sandler 37th Annual Healthcare Conference December 3, 2025 11:30 AM ESTCompany ParticipantsUptal Patel - Chief Medical...",
      "url": "https://finnhub.io/api/news?id=e69020844686310ebfe1cda1056e6c51c2fdd4d024d5e63093673007663df2fb"
    }
  },
  {
    "ts": null,
    "headline": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
    "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
    "url": "https://finnhub.io/api/news?id=dd62313fe6e190659e08c0a4b422f1fce66c4b81cf03b38bb9a8ba1c04e728cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764764781,
      "headline": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
      "id": 137670999,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
      "url": "https://finnhub.io/api/news?id=dd62313fe6e190659e08c0a4b422f1fce66c4b81cf03b38bb9a8ba1c04e728cd"
    }
  }
]